Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

URGENT: Japan secures extra Pfizer vaccine doses for 25 mil. people

05/14/2021 | 07:48am EDT

Japan has signed a contract with U.S. pharmaceutical giant Pfizer Inc. to receive additional doses of its coronavirus vaccine for 25 million people by September, health minister Norihisa Tamura said Friday.

The double-dose vaccine developed by Pfizer and its German partner BioNTech SE is the only approved COVID-19 vaccine in the country so far.

Under the agreement, Japan will receive 50 million doses, Tamura said.

==Kyodo

© Kyodo News International, Inc., source Newswire

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -0.53% 238.55 Delayed Quote.192.63%
PFIZER, INC. -1.30% 40.15 Delayed Quote.9.07%
All news about PFIZER, INC.
05:48aASTRAZENECAá : Germany demands that J&J make up COVID-19 vaccine gap in July
RE
06/11MODERNA, GAMESTOP, AMAZON.COM : Stocks That Defined the Week
DJ
06/11COVID SCIENCE-Vaccines effective vs variants despite diminished antibodies; k..
RE
06/11FDA Approves Export of Covid-19 Vaccine Doses From Troubled Baltimore Plan --..
DJ
06/11JOHNSON & JOHNSONá : US FDA Clears 10 Million Johnson & Johnson COVID-19 Vaccine..
MT
06/11PFIZERá : XELJANZ« Safety Review Recommendation Issued in the European Union
PU
06/11Do I Need a Covid-19 Vaccine Booster Shot?
DJ
06/11FDA Approves Export of Covid-19 Vaccine Doses from Troubled Baltimore Plant
DJ
06/11Brazil Approves Pfizer/BioNTech COVID-19 Vaccine For Children 12-15 Years Old
MT
06/11Can Schools Mandate Covid-19 Vaccines for Children? What We Know
DJ
More news
Financials (USD)
Sales 2021 72 162 M - -
Net income 2021 17 466 M - -
Net Debt 2021 26 268 M - -
P/E ratio 2021 13,6x
Yield 2021 3,92%
Capitalization 225 B 225 B -
EV / Sales 2021 3,48x
EV / Sales 2022 4,09x
Nbr of Employees 78 500
Free-Float 59,2%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 24
Average target price 42,09 $
Last Close Price 40,15 $
Spread / Highest target 32,0%
Spread / Average Target 4,83%
Spread / Lowest Target -10,3%
EPS Revisions
Managers and Directors
NameTitle
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER, INC.9.07%224 747
JOHNSON & JOHNSON4.82%434 405
ROCHE HOLDING AG10.68%328 612
NOVARTIS AG-0.39%208 035
ABBVIE INC.7.72%203 857
ELI LILLY AND COMPANY32.72%203 704